Treatment is changing rapidly. Traditional approaches are increasingly complemented by targeted biologics, immune-modulating medicines, digital monitoring tools, advanced imaging, and personalized treatment strategies.

The growing focus on early diagnosis is also important. Identifying inflammation before significant structural damage occurs can give physicians more opportunities to manage disease progression and improve quality of life.was valu5.

• Growth is projected at a 5.85% CAGR between 2026 and 2035.
• North America accounted for approximately 40% of revenue in 2024.
• Asia-Pacific is expected to record the fastest growth, with an estimated CAGR of around 12%.hibitors represented the leading drug class, accounting for approximately 45% in 2024.
• IL-17 inhibitors are expected to record strong growth as targeted treatment options expand.
• Subcutaneous administration represented approximately 50% of revenue in 2024.
• MRI remained the leading diagnostic method, with around 40% share.tals accounted for approximately 45% of end-user revenue in 2024.

Biologics Are Reshaping Treatment

TNF inhibitors have played a major role in AS treatment for years. Medicines such as adalimumab, infliximab, and etanercept work by blocking tumor necrosis factor, helping reduce inflammation and improve symptoms.

At the same time, IL-17 inhibitors are gaining attention. Therapies such as secukinumab and ixekizumab target the IL-17 pathway and are becoming increasingly important for patients who need targeted treatment.

The development of newer immune-modulating therapies could provide physicians with more options for patients who do not respond adequately to existing treatments.

AI Brings Smarter Diagnosis and Monitoring

Artificial intelligence is beginning to influence several stages of AS care.

AI and machine learning can assist physicians in analyzing X-ray and MRI images, identifying subtle inflammatory changes, and monitoring disease progression. Digital tools and wearable technologies can also help track mobility, pain, stiffness, and treatment responses outside traditional clinical settings.

This combination of imaging, patient-generated data, and predictive analytics could support more personalized treatment decisions in the future.

MRI Remains Central to Early Detection

MRI continues to play an important role because it can detect inflammatory changes that may not be visible through conventional X-rays, particularly during earlier stages of disease.

At the same time, digital spine monitoring tools are emerging as a promising area. Smartphone applications, wearable sensors, and remote monitoring platforms could make it easier for healthcare professionals to follow patients over longer periods.

Blood biomarkers and HLA-B27 genetic testing are also contributing to the broader diagnostic ecosystem.

Hospitals Lead While Specialty Clinics Gain Momentum

Hospitals currently represent the largest end-user group. Their advanced infrastructure, multidisciplinary teams, diagnostic capabilities, and access to specialized medicines make them important centers for AS treatment and clinical research.

However, specialty rheumatology clinics are expected to expand rapidly. These facilities can provide focused care, personalized treatment plans, rehabilitation services, and ongoing disease monitoring in an outpatient setting.

This shift could make AS management more accessible and convenient for patients.

North America Leads the Way

North America currently holds a leading position, supported by advanced healthcare infrastructure, strong pharmaceutical and biotechnology capabilities, extensive clinical research, and access to innovative therapies.

The United States remains a major center for AS research and clinical development. A well-established clinical trial ecosystem and strong presence of pharmaceutical companies continue to support innovation in biologics and targeted therapies.

Canada is also expanding its capabilities through greater awareness of autoimmune diseases, improved diagnosis, and growing adoption of advanced biologic treatments.

Asia-Pacific Could Become the Fastest-Growing Region

Asia-Pacific is emerging as an important growth area due to increasing healthcare investment, a large patient population, improving diagnostic capabilities, and expanding biotechnology activity.

China is strengthening its rheumatology ecosystem while increasing efforts to improve access to specialized care.

India is also gaining momentum as healthcare infrastructure expands and awareness of autoimmune diseases improves. Greater availability of biologics, specialty clinics, diagnostic technologies, and research initiatives could further strengthen treatment options for patients.

Europe Continues to Invest in Personalized Care

Europe benefits from established healthcare systems, pharmaceutical research capabilities, and regulatory frameworks supporting innovative therapies.

The UK continues to support research through organizations such as UK Research and Innovation and the National Institute for Health and Care Research.

Germany is also an important center for pharmaceutical research and advanced healthcare, with increasing interest in biologic therapies, early diagnosis, and personalized approaches to inflammatory diseases.

Competitive Landscape

Several major pharmaceutical companies are shaping the future of ankylosing spondylitis treatment.

Novartis has a strong position through Cosentyx (secukinumab), an IL-17A inhibitor used in AS.

AbbVie has extensive experience in immunology, with Humira (adalimumab) being an established TNF inhibitor for AS.

Other important companies include Pfizer, Eli Lilly, Johnson & Johnson, Gilead Sciences, Amgen, Sandoz, Samsung Biologics, Fresenius Kabi, and emerging biotechnology companies developing new targeted therapies and diagnostic technologies.

The competitive landscape is gradually moving beyond established TNF inhibitors toward newer mechanisms, oral therapies, biosimilars, digital diagnostics, and personalized treatment approaches.

Recent Industry Developments

In June 2026, Lynk Pharmaceuticals announced the completion of patient enrollment in a Phase III study of zemprocitinib for ankylosing spondylitis. The development represents another step toward expanding oral treatment options for patients.

In July 2025, Biocon Biologics launched Nepexto, a biosimilar of etanercept, in Australia through a collaboration with Generic Health, supporting broader access to biologic treatment.

In April 2025, Biocad, the Russian National Research Medical University of Pirogov, and the Institute of Bioorganic Chemistry collaborated on the development of Seniprutug, a domestic treatment intended for patients with AS.

What Comes Next?

The future of ankylosing spondylitis treatment will likely be shaped by three major developments: earlier diagnosis, more targeted therapies, and continuous patient monitoring.

Biologics and small-molecule therapies are expanding treatment choices, while AI and digital health technologies could improve diagnosis and long-term disease management.

At the same time, research into biomarkers, precision medicine, emerging immune therapies, and next-generation delivery systems could help physicians better match treatments to individual patients.

As innovation continues, the focus is shifting from simply controlling symptoms toward earlier intervention, personalized treatment, and better long-term mobility and quality of life.